Speedy Labs

Consumer Packaged Goods manufacturers have faced significant uncertainty in recent months, especially those that sell through a Foodservice or B2B route to market. In addition to inflation and cost volatility, manufacturers must deal with uncertainty around how often people are dining out and where they choose to eat. Consumer behavior

Economic and political shifts are creating uncertainty across the foodservice industry. Rising costs, changing consumer behavior, and supply chain disruptions are forcing operators and consumer products manufacturers to reconsider how they approach pricing, portions, and product packaging. Price Pack Architecture (PPA) provides a structured approach for adjusting value without relying

Pricing has never been easy for CPG manufacturers serving foodservice. Today, it is even more complicated. Persistent inflation, shifting trade policies, and supply chain instability are forcing companies to rethink how prices are set and adjusted. The central question facing commercial and finance teams is straightforward: Do you increase prices

Inflation is no longer a short headline. It is showing up in raw materials, packaging, labor, fuel, and freight — month after month. Many B2B manufacturers and foodservice operators initially chose to absorb rising costs. It felt responsible. Customers were under pressure too. But sustained inflation forces a harder question: How

Many consumer products manufacturers operate across two routes to market: retail and foodservice. At first glance, it may seem practical to manage both inside one system. In reality, the commercial models behind these channels are structured very differently. When a system is built around retail trade promotion logic, friction appears

The drug supply chain is a complex system made up of multiple stakeholders, each responsible for moving medications from development to the patient. Understanding how this system works is especially important as drug prices remain a major concern for consumers, healthcare providers, and policymakers. Rebates play a meaningful role within

When it comes to pharmacy benefits, few topics generate as much debate as rebates. Often presented as a major source of savings, rebates have become central to how pharmacy benefit plans are structured. Yet for many plan sponsors and consultants, the real value of rebates is difficult to assess. Rebates

Negotiating a Pharmacy Benefit Manager (PBM) contract is one of the most important financial decisions a plan sponsor can make. PBMs control pricing, discounts, rebates, and classification rules that directly affect total drug spend. While PBM contracts may appear straightforward on the surface, subtle language choices can materially shift value

Managing pharmaceutical and medical rebates in healthcare organizations requires careful coordination across purchasing, claims, billing, and formulary operations. When these processes are not aligned, organizations risk missed revenue, higher drug costs, and unnecessary administrative burden. Improving rebate management depends on strengthening three connected areas: rebate operations, claims adjudication, and therapeutic

The U.S. pharmaceutical industry continues to dominate global revenue, accounting for nearly half of worldwide pharma sales. Yet behind this scale sits a dense system of pricing arrangements, regulatory demands, and financial adjustments. Among the most influential elements in this system are rebates and chargebacks—two mechanisms that directly

Accurate revenue calculation is critical in the pharmaceutical industry, where pricing complexity, regulatory oversight, and multiple deduction layers directly affect financial reporting and compliance. The Gross-to-Net (GTN) process sits at the center of this effort, translating gross sales into actual realized revenue by accounting for rebates, discounts, chargebacks,

Pharmacy benefit managers, commonly known as PBMs, play a central yet often debated role in how Americans access prescription medications. In recent years, PBMs have drawn increased attention from the media and policymakers at both the federal and state levels. Still, because they work largely behind the scenes within the

Pharmaceutical rebates play a central role in drug pricing, formulary positioning, and financial planning. While they help manufacturers compete for market access, their complexity often creates operational and reporting challenges. Improving how rebates are managed requires tightening processes that already exist—contracts, compliance, data, tiering, and technology—rather than introducing

Revenue recognition is a critical component of financial reporting in the pharmaceutical industry. The mix of licensing deals, supply arrangements, milestone payments, and services creates a landscape where timing and valuation must be handled with precision. Because of this complexity, companies rely on the principles of ASC 606, the standard

Managing rebates in the pharmaceutical sector is a central financial responsibility. Because rebates affect revenue, margins, compliance, and partner relationships, connecting rebate processes with financial reporting is essential for an accurate picture of business performance. When rebate activity is aligned with financial systems, companies gain clearer insight into pricing, contractual

Incentive compensation plays a central role in guiding pharmaceutical sales teams toward the outcomes that matter most for the organization. Because the industry operates with complex regulations, intricate data requirements, diverse territories, and constantly shifting market conditions, designing and managing these programs demands precision and structure. A strong incentive framework

Incentive compensation in the pharmaceutical industry plays a major role in shaping sales performance, guiding behavior, and supporting organizational goals. It is designed to motivate sales representatives while keeping their daily actions aligned with broader business priorities. When managed well, it creates a dependable and focused sales force that contributes